logo.jpg
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
November 11, 2020 07:00 ET | ImCheck Therapeutics SAS
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01 Preliminary EVICTION Phase I/IIa trial data shows...
logo.png
Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors
November 10, 2020 01:08 ET | Immunophotonics, Inc.
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated...
22157.jpg
Global T-Cell Immunotherapy Markets 2020-2025 by Mechanism Of Action, Type of Therapy, Product Class
October 20, 2020 05:18 ET | Research and Markets
Dublin, Oct. 20, 2020 (GLOBE NEWSWIRE) -- The "T-Cell Immunotherapy Market Research Report by Mechanism Of Action, by Product Class - Global Forecast to 2025 - Cumulative Impact of COVID-19" report...
logo.png
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 10:13 ET | ImmunoPhotonics, Inc.
ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the...
logo.png
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 04:13 ET | ImmunoPhotonics, Inc.
BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:05 ET | Harpoon Therapeutics
Presented positive interim Phase 1 clinical trial data for PSMA-targeting HPN424 in prostate cancer at ASCO20, supporting increased dose escalation Dosed first patient with HPN217 targeting BCMA for...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
August 05, 2020 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
June 08, 2020 08:00 ET | TeneoBio, Inc
NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
November 12, 2019 16:05 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 06, 2019 16:05 ET | Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment of prostate and ovarian...